Related Experiment Videos
Oxaprozin-induced fulminant hepatitis
P P Purdum1, S L Shelden, J W Boyd
1Department of Internal Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond.
The Annals of Pharmacotherapy
|October 1, 1994
Summary
Oxaprozin, a nonsteroidal antiinflammatory drug (NSAID), has been linked to rare cases of severe liver injury. This study reports the first instance of oxaprozin-induced fulminant hepatic failure, emphasizing the need for liver function monitoring during NSAID therapy.
Area of Science:
- Hepatology
- Pharmacology
- Toxicology
Background:
- Nonsteroidal antiinflammatory drugs (NSAIDs) are widely used for pain and inflammation.
- While generally safe, NSAIDs can cause adverse effects, including liver injury (transaminitis).
- Oxaprozin is a long-acting NSAID with known potential for hepatic transaminase elevation.
Observation:
- A 56-year-old woman presented with acute liver failure.
- Extensive workup excluded other causes of liver injury.
- Oxaprozin use for two months prior to admission was the only significant finding.
- Liver biopsy revealed drug-induced hepatic injury, similar to diclofenac-induced cases.
Findings:
- This case represents the first documented instance of oxaprozin-induced fulminant hepatic failure.
- Oxaprozin, like other NSAIDs, can cause severe hepatotoxicity.
- The severity of liver injury may be associated with NSAID duration of use and patient factors.
Implications:
- Clinicians should be aware of the potential for severe liver injury with oxaprozin.
- Monitoring of liver function enzymes is crucial during NSAID therapy, especially in the elderly or those on concurrent hepatotoxic medications.
- This rare but serious adverse event underscores the importance of vigilant pharmacovigilance for NSAIDs.